Experimental Approaches for the Treatment of Infectious Disease

Tuesday April 27, 2021

2:00 pm - 3:30 pm Central Time (CT)

View session on the EB Virtual Platform (EB registration required)


Chair :

Ross Corriden

Ericka Anderson
University of California, San Diego

The COVID-19 pandemic highlights the need for development of novel anti-infective agents. Although academic researchers and the biopharmaceutical industry have quickly responded to develop candidate therapies to address COVID-19, an even larger infectious disease challenge remains largely unaddressed: antibiotic resistance. Each year in the US, 2.8 million people are infected with antibiotic-resistant pathogens; 35,000 die as a result of such infections. The 2014 UK Government Review on Antimicrobial Resistance concluded that, without a dramatic change in our response, antimicrobial resistance will result in 300 million premature deaths and up to $10 trillion in loss to the global economy by 2050, exceeding cancer as a cause of human mortality. Particularly at risk are patients already more vulnerable to illness from viral lung infections such as COVID-19; in fact, the CDC estimates that 29%-55% of the deaths recorded during the 2009 H1N1 influenza pandemic were caused by secondary bacterial pneumonia. Many major pharmaceutical companies have abandoned antibiotic R&D after judging it to be unprofitable, creating an innovation gap. Furthermore, because of frequent use of antibiotics for self-resolving issues, physician reliance on unnecessarily broad-spectrum regimes, widespread use of antibiotics in agricultural feed for growth promotion, and pure Darwinian evolution of bacteria, we face a dilemma where new anti-infective approaches are needed. This symposium highlights translational research efforts aimed at resolving this unmet medical need. Since initial submission for EB2020, this session has been adjusted with a renewed focus on respiratory tract infections.


Lauren Bakaletz - Ohio State University College of Medicine; Scioto Biosciences

Targeting the Biofilm Matrix for Disruption Results in Newly Released (NRel) Bacteria with Markedly Increased Sensitivity to Traditional Antibiotics that are Otherwise ineffective Against Biofilms

Antibody-mediated release of bacteria from biofilm residence into the surrounding milieu supports an approach to resolve otherwise difficult-to-treat biofilm-associated diseases. We show that the unique phenotype of the newly released (NRel) bacteria is dependent upon the specific mechanism of release from biofilm residence. The resulting NRel populations are significantly different from each other despite genetic identity, and each NRel population has a distinct, significantly increased susceptibility to antibiotic-mediated killing, which suggests the potential for this approach to mitigate overuse of antibiotics for treatment of these recalcitrant infections.

Liangfang Zhang - University of California, San Diego

Biomimetic Nanoparticles for the Treatment of Infectious Diseases

The talk discusses the biological functionalization of polymeric nanoparticles with a layer of membrane coating derived from natural cells. He will focus on the use of these cell-mimicking nanoparticles for the treatment of bacterial and viral infections.

Lynette Cegelski - Stanford University

Vancomycin Conjugates Yield Extraordinary New Activities Against Gram-positive and Gram-negative Bacteria

Talk description coming soon.

David Gonzalez - University of California, San Diego, School of Medicine and Pharmacy

Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures

Multi-omic analysis of serum from patients with Staphylococcus aureus bacteremia performed by Dr. Gonzalez’s team identified features with predictive value to determine disease mortality and guide treatment decisions.

Last Updated: February 8, 2021
Key Dates
April 27 – 30, 2021

ASPET Annual Meeting at EB 2021

Thank you to our Annual Meeting partners: